Panvax(®)：一种针对 2009 年甲型 H1N1 流感的单价、灭活、无佐剂疫苗。
Panvax(®): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009.
机构信息
Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and Melbourne School of Population Health, The University of Melbourne, Parkville, Victoria 3010, Australia.
出版信息
Expert Rev Vaccines. 2011 Jan;10(1):35-43. doi: 10.1586/erv.10.143.
Panvax(®) (CSL Biotherapies, Parkville, Australia) is one of a number of pandemic influenza A (H1N1) 2009 (pH1N1) vaccines fast-tracked for production, clinical trials and licensure in response to the emergence of the novel pH1N1 strain in early-mid-2009. Unexpectedly good immunogenicity following a single 15-µg dose was demonstrated in expedited clinical trials in adults and children. This facilitated early licensure and then rapid rollout for population immunization from October 2009. The vaccine's safety profile in the Australian population has been excellent.
Panvax(®)（CSL Biotherapies，澳大利亚帕克维尔）是为应对 2009 年初新型 pH1N1 株的出现而快速生产、临床试验和许可的多种大流行性流感 A（H1N1）2009（pH1N1）疫苗之一。在加速进行的成人和儿童临床试验中，单剂 15µg 时表现出出乎意料的良好免疫原性。这促进了早期许可，随后于 2009 年 10 月开始快速进行人群免疫接种。该疫苗在澳大利亚人群中的安全性良好。
Zotero 插件